NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas

• Joonas Haapasalo ^[1] ; Kristiina Nordfors ^[1] ; Kirsi J. Granberg ^[4] ; Tomi Kivioja ^[1] ; Matti Nykter ^[2] ; Hannu Haapasalo ^[5] ; Ylermi Soini ^[3]
  1. [1] Tampere University Hospital

     Tampere University Hospital

     Tampere, Finlandia

     
  2. [2] University of Tampere

     University of Tampere

     Tampere, Finlandia

     
  3. [3] University of Eastern Finland

     University of Eastern Finland

     Kuopio, Finlandia

     
  4. [4] Science Center, Tampere University Hospital, Finland
  5. [5] Department of Pathology, Fimlab Laboratories, Tampere, Finland

  Mostrar afiliaciones +
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 33, Nº. 8, 2018, págs. 791-801
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Nuclear factor erythroid 2-related factor 2 (NRF2), DJ1 and sulfiredoxin 1 (SRXN1) are transcription factors which protect cells from the oxidative damage caused by reactive oxygen species and, on the other hand, are associated with resistance to cancer treatments. The immunohistochemical expression of NRF2, DJ1 and SRNX1 was assessed in human grade II-IV astrocytic gliomas. Their association to clinicopathologic and essential molecular factors was evaluated. The RNA expression levels and genetic alterations were analyzed from publicly available datasets. All studied molecules were commonly expressed. The cytoplasmic NRF2 expression was higher in tumors with a higher malignancy grade, whereas the nuclear and cytoplasmic DJ1 expression was associated with a lower grade. The presence of the isocitrate dehyrdogenase 1 mutation (IDH1) was associated with an increasing cytoplasmic and nuclear expression of NRF2 and a nuclear DJ1 expression.

    When primary grade IV astrocytomas were compared to secondary glioblastomas, nuclear DJ1 was associated with secondary tumors. In grade II-IV tumors, the cytoplasmic NRF2 expression was associated with a poor prognosis, whereas nuclear NRF2 and both cytoplasmic and nuclear DJ1 were associated with a better patient prognosis. Recurrent homozygous deletions of DJ1 were observed, especially in the IDH wild-type samples. When only the glioblastomas were evaluated, nuclear NRF2 and SRNX1 predicted better survival. As a conclusion, NRF2, DJ1 and SNXR1 can be used as prognosticators in gliomas.